416 related articles for article (PubMed ID: 28153956)
1. Influence of Bevacizumab on Blood-Brain Barrier Permeability and
Stegmayr C; Oliveira D; Niemietz N; Willuweit A; Lohmann P; Galldiks N; Shah NJ; Ermert J; Langen KJ
J Nucl Med; 2017 May; 58(5):700-705. PubMed ID: 28153956
[TBL] [Abstract][Full Text] [Related]
2. Influence of blood-brain barrier permeability on O-(2-
Stegmayr C; Bandelow U; Oliveira D; Lohmann P; Willuweit A; Filss C; Galldiks N; Lübke JH; Shah NJ; Ermert J; Langen KJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):408-416. PubMed ID: 27613541
[TBL] [Abstract][Full Text] [Related]
3. Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas.
Stegmayr C; Schöneck M; Oliveira D; Willuweit A; Filss C; Galldiks N; Shah NJ; Coenen HH; Langen KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1115-23. PubMed ID: 26646781
[TBL] [Abstract][Full Text] [Related]
4. Treatment-Related Uptake of
Geisler S; Stegmayr C; Niemitz N; Lohmann P; Rapp M; Stoffels G; Willuweit A; Galldiks N; Filss C; Sabel MC; Coenen HH; Shah NJ; Langen KJ
J Nucl Med; 2019 Oct; 60(10):1373-1379. PubMed ID: 30850492
[TBL] [Abstract][Full Text] [Related]
5. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings.
Doi Y; Kanagawa M; Maya Y; Tanaka A; Oka S; Nakata N; Toyama M; Matsumoto H; Shirakami Y
Nucl Med Biol; 2015 Aug; 42(8):664-72. PubMed ID: 26022202
[TBL] [Abstract][Full Text] [Related]
7. Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat.
Spaeth N; Wyss MT; Pahnke J; Biollaz G; Lutz A; Goepfert K; Westera G; Treyer V; Weber B; Buck A
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):673-82. PubMed ID: 16538503
[TBL] [Abstract][Full Text] [Related]
8. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
11. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
12. Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic.
Hutterer M; Ebner Y; Riemenschneider MJ; Willuweit A; McCoy M; Egger B; Schröder M; Wendl C; Hellwig D; Grosse J; Menhart K; Proescholdt M; Fritsch B; Urbach H; Stockhammer G; Roelcke U; Galldiks N; Meyer PT; Langen KJ; Hau P; Trinka E
J Nucl Med; 2017 Jan; 58(1):129-137. PubMed ID: 27469356
[TBL] [Abstract][Full Text] [Related]
13. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
14. 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas.
Sai KK; Huang C; Yuan L; Zhou D; Piwnica-Worms D; Garbow JR; Engelbach JA; Mach RH; Rich KM; McConathy J
J Nucl Med; 2013 Jul; 54(7):1120-6. PubMed ID: 23650628
[TBL] [Abstract][Full Text] [Related]
15. Comparison of [
Shymanskaya A; Worthoff WA; Stoffels G; Lindemeyer J; Neumaier B; Lohmann P; Galldiks N; Langen KJ; Shah NJ
Mol Imaging Biol; 2020 Feb; 22(1):198-207. PubMed ID: 30989437
[TBL] [Abstract][Full Text] [Related]
16. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
17. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors.
Pauleit D; Floeth F; Tellmann L; Hamacher K; Hautzel H; Müller HW; Coenen HH; Langen KJ
J Nucl Med; 2004 Mar; 45(3):374-81. PubMed ID: 15001676
[TBL] [Abstract][Full Text] [Related]
18. Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas.
Piroth MD; Prasath J; Willuweit A; Stoffels G; Sellhaus B; van Osterhout A; Geisler S; Shah NJ; Eble MJ; Coenen HH; Langen KJ
Nucl Med Biol; 2013 Aug; 40(6):795-800. PubMed ID: 23769262
[TBL] [Abstract][Full Text] [Related]
19. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.
Hutterer M; Nowosielski M; Putzer D; Jansen NL; Seiz M; Schocke M; McCoy M; Göbel G; la Fougère C; Virgolini IJ; Trinka E; Jacobs AH; Stockhammer G
Neuro Oncol; 2013 Mar; 15(3):341-51. PubMed ID: 23335162
[TBL] [Abstract][Full Text] [Related]
20. Preferred transport of O-(2-[18F]fluoroethyl)-D-tyrosine (D-FET) into the porcine brain.
Makrides V; Bauer R; Weber W; Wester HJ; Fischer S; Hinz R; Huggel K; Opfermann T; Herzau M; Ganapathy V; Verrey F; Brust P
Brain Res; 2007 May; 1147():25-33. PubMed ID: 17343835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
